CMS Open Payments · Program Year 2024
Abanza Inc.
Abanza Inc. reported $3,525.56 across General Payments, Research, and Ownership to 33 physicians and teaching hospitals across 33 transactions.
- $3.5K Below-median payer
- All-tracks total
- 33 Below-median volume
- Transactions
- 33 Below-median reach
- Recipients
- #1752
- of 1,925 companies
Abanza Inc. reported $3,525.56 across all CMS Open Payments tracks (General + Research + Ownership) to 33 physicians and teaching hospitals in Program Year 2024 - ranking #1752 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,525.56, averaging $106.84 per recipient.
Abanza Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer abanza-inc Abanza Inc.
$3.5K · #1752/1,925 · 0.0% industry · PY2024
- TOT $3.5K
- RANK #1752
- SHARE 0.0%
- TXN 33
- RCP 33
- CAT 1
- GEN $3.5K
- TOP1 8.1%
- PY 2024
Volume peers
Nearest volume peer: Argentum Medical ($3.5K)
Abanza Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Abanza Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Abanza Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $3.5K, accounting for 100.0% of this company's General Payments and 33 transactions.
General Payment Breakdown by Type
Abanza Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $3.5K, 100.0% of General Payments.
How Abanza Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $3.5K | 33 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,334.10 (37.8%) of $3,525.56 in this company's General Payments records across 28 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Abanza Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Michael Schwartz
$285.04 across 2 reported transactions
- 2
Dean Papaliodis
$270.93 across 2 reported transactions
- 3
Allison Ganter
$270.93 across 2 reported transactions
- 4
Damond Blueitt
$253.60 across 1 reported transactions
- 5
Shankar Das
$253.60 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Abanza Inc. ranks #1752 of 1,925 by total payments (bottom 9% by spend) but is notably more concentrated than that alone would suggest -- #1,267 of 1,838 by HHI (bottom 31% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Chugai Pharmaceutical Co., Ltd. : $494.0K total payments, HHI 550
- Novocure Inc. : $1.2M total payments, HHI 549
- Blue Surgical Llc : $12.0K total payments, HHI 549
- IBA Proton Therapy, Inc. : $24.6K total payments, HHI 548
- Rattan And Associates : $17.3K total payments, HHI 548
- Apellis Pharmaceuticals, Inc. : $3.5M total payments, HHI 546
- Abanza Inc. (this company) : $3.5K total payments, HHI 546
- Pajunk Medical Systems, LP : $4.4K total payments, HHI 538
- Cagent Vascular INC : $103.5K total payments, HHI 534
- ImmunoGen, Inc. : $95.7K total payments, HHI 533
- TELA Bio, Inc. : $2.1M total payments, HHI 531
- Medistim USA, Inc. : $4.8K total payments, HHI 530
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Abanza Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Abanza Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Abanza Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Wardlow Enterprises
Avion Pharmaceuticals
FFF Enterprises, Inc.
Veran Medical Technologies, Inc.
Lifeward, Inc.
Put this to use
Abanza Inc. ranks #1752 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Abanza Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.